NCT05313152View on ClinicalTrials.gov

Study of TAVO103A in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

April 26, 2023

Study Completion Date

June 8, 2023

Conditions
Healthy Subjects
Interventions
DRUG

TAVO103A

TAVO103A single ascending dose IV infusion.

OTHER

Placebo

Placebo single ascending dose IV infusion.

Trial Locations (1)

84124

ICON, Salt Lake City

Sponsors
All Listed Sponsors
lead

Tavotek Biotherapeutics

INDUSTRY

NCT05313152 - Study of TAVO103A in Healthy Volunteers | Biotech Hunter | Biotech Hunter